KRAS and colorectal carcinoma: Our results are in close agreement, with TP53 (63%), KRAS (59%), APC (50%), PIK3CA (20%), SMAD4 (11%), FBXW7 (11%), NRAS (11%), and BRAF (7%), confirming cross-population consistency in CRC mutational patterns.